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Abstract
Background Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years
and include cytotoxic agents (e.g., docetaxel and cabazitaxel), immunotherapy (e.g., sipuleucel-T), oral hormonal therapies
targeting the androgen receptor axis (e.g., enzalutamide and abiraterone), and targeted alpha therapy (e.g., radium-223
dichloride (radium-223)). Although treatment guidelines have been updated to reﬂect the availability of new agents, it is not
easy to apply them in daily clinical practice because recommendations vary depending on patient comorbidities and disease
characteristics. Furthermore, therapeutic accessibility, clinical judgment, and experience affect the selection of treatment
options.
Methods In this review, we provide practical guidance for the integration of radium-223 into the management of patients
with mCRPC based on our collective clinical experience, as well as the available clinical trial data.
Results Radium-223 is a targeted alpha therapy; as a bone-seeking calcium mimetic, it accumulates in hydroxyapatite areas
surrounding tumor lesions and selectively binds to the areas of increased bone turnover. Radium-223 prolongs overall
survival and delays time to the ﬁrst symptomatic skeletal events in men with mCRPC, and is indicated for the treatment of
patients with CRPC, symptomatic bone metastases, and no known visceral metastases. We review its clinical efﬁcacy and
safety, practical guidance on identifying the appropriate patient, and recommendations for how best to educate and inform
prospective patients regarding their treatment decision making. In addition, we review recent evidence for sequential and
combination therapies with radium-223, provide our experiences with these treatment approaches, and discuss their
implications for the future treatment of patients with mCRPC.
Conclusions Based on our clinical experience, radium-223 should be considered relatively early in the treatment course in
patients with mCRPC with bone metastases. Coordination of care among multidisciplinary team members, patients, and
caregivers is essential for optimizing safe and effective treatment with all CRPC therapies.
Introduction
Metastatic castration-resistant prostate cancer (mCRPC) has
been shown to predominantly metastasize to bone and fre-
quently spread to visceral organs and soft tissue as well.
Bone metastases occur in up to 90% of patients with
mCRPC [1–3], and may be associated with signiﬁcant
clinical complications, including pain [4]; skeletal-related
events (SREs), such as pathologic fractures and spinal cord
compression [5]; and reduced patient mobility, with quality-
of-life (QoL) impairment [4]. Furthermore, the presence of
bone metastases is associated with reduced overall survival
(OS) [6, 7]. Visceral metastases are less common, but have
been observed in ~10% [8] of newly diagnosed patients
with mCRPC, increase over time and may affect as many as
49% of men with prostate cancer–speciﬁc mortality [1, 3].
Over the last several years, treatment options for mCRPC
have expanded and now include cytotoxic agents (e.g.,
docetaxel and cabazitaxel), oral hormonal therapies target-
ing the androgen receptor axis (e.g., enzalutamide and
abiraterone), targeted alpha therapy (radium-223), immu-
notherapy (e.g., sipuleucel-T), and bone supportive agents
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that target bone resorption and reduce SREs (e.g., denosu-
mab and zoledronic acid) [9, 10]. There are several treat-
ment guidelines for mCRPC, including those from the
American Urological Association, European Association of
Urology, National Comprehensive Cancer Network, Cana-
dian Urological Association, and European Society for
Medical Oncology [10–15]. However, despite the abun-
dance of guidelines, it is not always obvious how to best
apply them in daily clinical practice when making decisions
concerning sequencing and/or combination strategies
because recommendations vary depending on patient
comorbidities and speciﬁc patient disease characteristics.
The guidelines typically present a range of treatment
options at each stage of the patient journey. In addition, the
approach to treatment may vary across clinical practice
settings, speciﬁcally considering the clinical experience of
the physician with the varying approved therapies, and thus
possible inherent biases, which may affect the multi-
disciplinary team involved.
Radium-223 is one of several approved therapies for
mCRPC that have been shown to improve OS in patients
with mCRPC (Table 1) [1, 16–23]. Ideally, a patient should
receive all of the approved therapies during their patient
journey. However, all of these CRPC therapies were
developed in relatively concurrent trials over the last several
years, and published prospective data on their sequential
and combined use are severely lacking. Thus, the challenge
is to determine the optimum sequence or combination of
therapies in the absence of level-one evidence that might
help improve speciﬁc patient outcomes.
Methods
In this review, we provide guidance regarding the integra-
tion of radium-223 into the management of patients with
mCRPC based on our collective clinical experience, as well
as the available clinical trial data.
Results
Overview of clinical trial data
Radium-223 was approved based on the results of the
international, prospective, randomized, double-blind,
placebo-controlled phase 3 ALSYMPCA trial in patients
with symptomatic mCRPC and bone metastases. This trial
demonstrated that radium-223 plus best standard of care
signiﬁcantly improved OS, leading to a 30% reduction in
the risk of death compared with placebo plus best standard
of care (Table 2) [18]. Secondary analyses further supported
the beneﬁt of radium-223, demonstrating that radium-223
reduced the risk of symptomatic skeletal events (SSEs) and
signiﬁcantly delayed the time to the ﬁrst SSE [24], was
effective regardless of prior docetaxel use (Fig. 1) [25], and
provided a signiﬁcant improvement in patient QoL [26].
Healthcare resource utilization was also an endpoint in the
phase 3 study, and a signiﬁcantly smaller proportion of
patients experienced 1 or more hospitalizations with
radium-223 than with placebo (37.0% vs 45.5%, respec-
tively; P= 0.016) [27]. Exploratory analyses also showed
that efﬁcacy (i.e., OS and risk of SSE) was comparable in
patients who were symptomatic (baseline opioid use) and
minimally symptomatic (no opioid use) [28]. In addition,
radium-223 has a well-tolerated safety proﬁle, with a low
incidence of myelosuppression regardless of prior docetaxel
use [18, 25]. In the phase 3 trial, the most common adverse
events (AEs) were bone pain, nausea, and anemia (Table 2)
[18]. Ongoing phase 2 and 3 studies with radium-223 are
designed to evaluate high-dose and extended treatment
regimens, efﬁcacy in combination with the hormonal agents
Table 1 Efﬁcacy of therapies
for metastatic castration-resistant
prostate cancer
Therapy Comparator Improvement in median overall
survival (mo) vs comparator
Hazard
ratio
Enzalutamide
Prechemotherapy [68] Placebo 4.0 0.77
Postchemotherapy [17] Placebo 4.8 0.631
Radium-223+ best standard of
care [18]
Placebo+ best
standard of care
3.6 0.70
Cabazitaxel [19] Mitoxantrone 2.4 0.70
Abiraterone
Prechemotherapy [23] Placebo 4.4 0.81
Postchemotherapy [69] Placebo 4.6 0.74
Docetaxel [1] Mitoxantrone 2.4 0.76
Sipuleucel-T [22] Placebo 4.1 0.78
C. Parker et al.
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Radium-223 in Clinical Practice
abiraterone and enzalutamide, increased immune response
by sipuleucel-T against mCRPC, and treatment effects on
biomarkers (ClinicalTrials.gov NCT02043678, NCT02023697,
NCT02346526, NCT02034552, NCT02463799, and
NCT01929655).
Best clinical practices for treating patients with
radium-223
Treatment with radium-223
Practice guidelines for radium-223 use vary but generally
recommend radium-223 for patients with mCRPC with
symptomatic bone metastases [10, 12, 14, 15, 29, 30].
Based on our clinical experience and patient preferences,
we generally recommend the selection of less toxic treat-
ments ﬁrst in an effort to minimize the effect of treatment on
patient lifestyle and QoL and to preserve patient daily
function (i.e., performance status). Although subgroup
analysis of the phase 3 trial suggested that the efﬁcacy of
radium-223 is similar across all subgroups examined,
radium-223 is particularly appropriate for patients with
bone-only or bone-predominant disease.
Although the optimum sequence of life-prolonging
therapies is not known, there are several arguments for
using radium-223 relatively early in the course of mCRPC,
when there is a clinical window of opportunity before the
development of visceral metastases. In particular, the
probability of developing visceral metastases increases
over time, which then renders the patient ineligible for
radium-223 per the approved indication [3].
Radium-223 in symptomatic patients
The main purpose of treatment with radium-223 is to
improve survival, not to relieve symptoms. Thus, symptom
severity should not be used as an indication for radium-223
treatment initiation [28]. Further, the term ‘symptomatic’
1.0 2.0
Placebo
Better
Radium-223
Better
All patients
Total ALP level at baseline
<220 U/liter
≥220 U/liter
Current bisphosphonate use
Yes
No
Previous docetaxel use
Yes
No
Baseline ECOG performance-status score
0 or 1
≥2
Extent of disease
<6 metastases
6–20 metastases
>20 metastases
Superscan
Opioid use
Yes
No
)IC%59(oitaRdrazaH322-muidaR PlaceboSubgroup
0.70 (0.58–0.83)
0.70 (0.52–0.93)
0.68 (0.54–0.86)
0.71 (0.54–0.92)
0.64 (0.47–0.88)
0.95 (0.46–1.95)
0.71 (0.40–1.27)
0.68 (0.56–0.82)
0.82 (0.50–1.35)
0.74 (0.56–0.99)
0.71 (0.56–0.89)
0.74 (0.59–0.92)
0.70 (0.52–0.93)
0.62 (0.49–0.79)
0.5
0.82 (0.64–1.07)
614
348
266
250
364
352
262
536
77
100
262
195
54
345
269
307
169
138
124
183
174
133
265
41
38
147
91
30
168
139
no. of patients
Radium-223 Placebo
14.9
17.0
11.4
15.3
14.5
14.4
16.1
15.4
10.0
27.0
13.7
12.5
11.3
13.9
16.4
11.3
15.8
8.1
11.5
11.0
11.3
11.5
11.9
8.4
NE 
11.6
9.1
7.1
10.4
12.8
median overall survival (mo)
Fig. 1 Prospective subgroup analysis of hazard ratios for death in the
radium-223 ALSYMPCA trial [18]. The Eastern Cooperative Oncology
Group (ECOG) scores the performance status of patients with respect
to activities of daily living as follows: 0, fully active and able to carry
out all predisease activities without restriction; 1, restricted in physi-
cally strenuous activity but ambulatory and able to carry out work of a
light nature; 2, ambulatory and up and about for more than 50% of
waking hours and capable of self-care but unable to carry out work
activities; 3, capable of only limited self-care and conﬁned to a bed or
chair for more than 50% of waking hours; 4, completely disabled; and
5, dead. The category for use of opioids includes patients with a score
of 2 or 3 on the World Health Organization “ladder” for cancer pain (a
score of 1 indicates mild pain and no opioid use, 2 indicates moderate
pain and occasional opioid use, and 3 indicates severe pain and regular
daily opioid use). The category for non-use of opioids includes
patients without pain or opioid use at baseline and patients with a score
of 1 on the WHO ladder for cancer pain. Superscan refers to a bone
scan showing diffuse, intense skeletal uptake of the tracer without
renal and background activity. ALP denotes alkaline phosphatase, and
NE not evaluated. Reproduced with permission from Parker et al. [18]
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when describing bone metastases is broadly deﬁned,
includes patients who are pain-free on simple analgesia, and
may have subjective variation [31, 32].
In the phase 3 trial, symptomatic disease was deﬁned as
requiring regular use of analgesic medication or recent use
of external beam radiation therapy (EBRT) for cancer-
related bone pain [18, 28]. Radium-223 showed a similar
improvement in OS both in minimally symptomatic (i.e.,
patients not using opioid analgesics) and more symptomatic
patients with mCRPC [18, 28], suggesting that there is no
need to delay treatment with radium-223 until symptoms are
severe.
In our practices, radium-223 is generally used early in the
management of the disease if the patient exhibits sympto-
matic bone metastases with or without small volume pelvic
or retroperitoneal lymph node metastases, with no evidence
of visceral metastases, and with good hematologic function.
Symptomatic bone metastases are deﬁned either by actual
pain validated on a visual analog scale or by the use of pain
medication. The use of radium-223 before or after docetaxel
is always discussed with the patient. In addition, we base the
decision on several biological parameters, such as prostate-
speciﬁc antigen (PSA) doubling time, extent of extraosseous
disease, and time to castration resistance. In the presence of
poor prognostic markers, such as PSA doubling time
<6 months, response to androgen deprivation therapy
<12 months, elevated lactate dehydrogenase, and extensive
lymph node metastases, we favor the use of ﬁrst-line che-
motherapy. In the elderly patient, we suggest using screen-
ing tests to objectively assess health status (i.e., ﬁt,
vulnerable, or frail) and determine who might be an appro-
priate candidate for which type of therapy [33–35].
Concomitant use of radium-223 with other therapies for
CRPC
External beam radiation therapy Because radium-223 was
shown to be well tolerated in patients treated with best
standard of care, which included local EBRT or treatment
with glucocorticoids, antihormonals/antiandrogens, ketoco-
nazole, or estrogens [18], patients receiving any of these
therapies could potentially receive concomitant radium-223
treatment, if indicated. This is particularly appropriate in
those countries where it is not possible to use radium-223 in
combination with abiraterone or enzalutamide. In a phase 2
study, in which all patients received EBRT before study
drug, there was no signiﬁcant difference in hematologic
toxicity between radium-223 and placebo [36]. A post hoc
analysis of patients receiving EBRT and radium-223 from
the phase 3 trial demonstrated that concomitant EBRT did
not adversely affect the safety proﬁle of radium-223; the
incidence of myelosuppression was low, regardless of
concomitant use of EBRT [37]. The safety ﬁndings from the
phase 3 trial, as well as the non-overlapping mechanism of
action of radium-223 with other routine treatments for
mCRPC, suggest that the use of radium-223 in combination
with best standard of care is feasible in practice [18].
However, concomitant treatment of radium-223 with either
cytotoxic chemotherapy or other radionuclides was speci-
ﬁcally excluded from the phase 3 trial and should not be
used in routine practice unless prospective results become
available to support this approach.
Hormonal (antiandrogen) therapy A recent open-label
phase 2 study evaluating the combination of radium-223
plus abiraterone in patients with CRPC and symptomatic
bone disease reported a decrease in bone pain, an increase in
QoL measurements, and stability of ECOG scores com-
pared with the screening visit. Overall, a signiﬁcant
majority of patients had either absence of progressive dis-
ease or maintenance of stable disease (eRADicAte;
NCT02097303) [38]. A similar study is currently underway
evaluating enzalutamide with concurrent administration of
radium-223 in patients with CRPC and bone metastases
(EnzaRadiCate; NCT02507570). Several additional clinical
trials are in progress to investigate combination therapy of
radium-223 with either abiraterone or enzalutamide. A
phase 3 randomized, double-blind study of radium-223 or
placebo, each in combination with abiraterone plus pre-
dnisone in chemotherapy-naive patients with asymptomatic
or mildly symptomatic mCRPC with bone metastases (ERA
223; NCT02043678) was recently prematurely unblinded
[39]. The independent data monitoring committee (IDMC)
recommended unblinding the trial due to the observation of
more fractures and deaths in the combination treatment arm.
Unblinded data from the study are currently being analyzed
to conﬁrm the preliminary ﬁndings of the IDMC. Given
these results from ERA 223 trial, our current recommen-
dation is not to combine radium-223 with concomitant
abiraterone acetate and prednisone. A phase 3 multicenter,
randomized, open-label study comparing enzalutamide with
or without radium-223 in patients with asymptomatic or
mildly symptomatic mCRPC with bone metastases is
ongoing (PEACE III; NCT02194842).
Based on recent retrospective analyses, it seems there is
limited beneﬁt to sequential treatment with abiraterone and
enzalutamide in terms of reducing PSA or increasing
progression-free survival (PFS) [40]. Moreover, several
gene mutations known to occur in androgen receptors have
been linked to the development of resistance in response to
antiandrogen hormonal therapies, including a mutation that
may confer resistance to both abiraterone and enzalutamide
[41]. Radium-223 or chemotherapy therefore represents a
logical alternative treatment following disease progression
on either abiraterone or enzalutamide, rather than sequential
use of the other hormonal agent. The data from randomized
Radium-223 in Clinical Practice
controlled trials on the efﬁcacy of radium-223 following
treatment with either abiraterone or enzalutamide are not
available. However, given the lack of resistance to alpha
emitter therapy reported in the literature, we would not
expect prior treatment with either agent to affect the efﬁcacy
of radium-223.
Chemotherapy The optimum treatment sequence of
radium-223 relative to docetaxel has not been clinically
established. In the phase 3 trial, radium-223 was effective
regardless of prior docetaxel use [25]. In our practices,
radium-223 was primarily used after docetaxel when
radium-223 was ﬁrst approved; more recently, however,
radium-223 is typically used before docetaxel. The choice of
using docetaxel or radium-223 as the ﬁrst agent is generally
dependent on the presence of visceral metastases or symp-
tomatic bone disease [42]. More speciﬁcally, if visceral
disease is not present, then it may be better to use
radium-223 before chemotherapy because radium-223 is not
indicated for patients with visceral disease [43]. Radium-223
was shown to have a low incidence of myelosuppression in
the phase 3 trial; however, prior use of docetaxel therapy
(odds ratio (OR), 2.16; P= 0.035) and decreased hemoglo-
bin (OR, 1.35; P= 0.008) and platelet levels (OR, 1.44; P=
0.030) were shown to be risk factors for grades 2–4 throm-
bocytopenia, which occurred in 6% of patients receiving
radium-223 [44]. Consequently, patients with these baseline
risk factors should be monitored for hematologic toxicities
when receiving radium-223 after chemotherapy [44].
The safety and efﬁcacy of concomitant chemotherapy and
radium-223 have not been established, and current recom-
mendations are that radium-223 should not be given with
chemotherapy because of concerns about myelosuppression
[43,45]. Preliminary ﬁndings from a phase 1/2 trial regarding
the efﬁcacy and safety of radium-223 plus docetaxel vs
docetaxel monotherapy in patients with mCRPC found that
the combination was safe and that more patients treated with
combination therapy had normalized bone alkaline phospha-
tase (ALP) levels compared with patients treated with
docetaxel alone (39% vs 18% had a decrease >80%) [46].
Patients in the combination treatment group also had longer
median PFS compared with docetaxel monotherapy (6.2 vs
4.8 months) [47]. However, these ﬁndings should be validated
in a larger clinical study; the use of docetaxel in combination
with radium-223 cannot be recommended at present.
Bone-supportive agents Administration of radium-223
with bone-supportive agents, such as denosumab or
bisphosphonates, has shown good safety proﬁle in patients
with mCRPC. In a post hoc exploratory analysis, patients
receiving radium-223 with concomitant denosumab had
longer median OS compared with patients not treated with
denosumab (median OS, not available (95% CI, 15–not
available) months vs 13 (12–not available) months), and
both groups had a similar safety proﬁle. OS was generally
similar in patients treated with radium-223 with con-
comitant bisphosphonates vs those receiving radium-223
without bisphosphonates [48]. In addition, the ALSYMPCA
trial showed that patients receiving radium-223 who were
receiving bisphosphonates at study entry had a longer time
to ﬁrst SSE (median, 19.6 (95% CI, 16.5–not estimable)
months) vs patients not using bisphosphonates at study
entry (11.8 (19.3–13.6) months) [24].
Monitoring radium-223 efﬁcacy in patients
In the phase 3 study, imaging was not routinely performed
to determine response in bone because conventional com-
puted tomography (CT) scan and Tc bone scan are not
considered to be reliable methods to ascertain response in
bone [18]. Use of the bone scan index to analyze bone scan
ﬁndings may be more appropriate. Also, CT may be useful
to detect disease progression in areas other than bone and a
recent retrospective analysis supports the use of imaging by
CT after 3 and 6 doses of radium-223 in order to conﬁrm
there has been no extraskeletal disease progression [49]. A
number of imaging methods, such as C-11/F-18-choline, F-
18-FACBC, and Ga-68-PSMA for positron emission
tomography (PET) combined with CT (PET/CT) or mag-
netic resonance imaging (MRI), are currently under inves-
tigation to determine their utility for response assessment in
prostate cancer and cannot yet be recommended for use in
routine clinical practice. Our recent clinical experience with
diffusion-weighted MRI appears initially promising in the
assessment of response to radium-223 treatment [50].
Recently published ﬁndings from a prospective magnetic
resonance substudy of a phase 2 trial of olaparib in mCRPC
provide some preliminary evidence of the feasibility of
whole-body diffusion-weighted imaging for assessment of
bone metastases in patients with mCRPC [51]. However,
further evaluation and validation of this approach are
needed.
Other routine measurements that we use to assess clinical
response and disease progression in our clinical practices
include ALP and PSA levels. However, it should be noted
that although radium-223 improves survival by 30%, it has
a relatively modest effect on serum PSA levels. Speciﬁcally,
≥30% reductions in PSA blood levels in the phase 3 trial
were achieved by only 16% of patients receiving
radium-223 plus best standard of care vs 6% for placebo
plus best standard of care (P< 0.001) [18]. These PSA
results are attributed to the mechanism of action of
radium-223 which, like immunotherapy, does not target the
androgen receptor and has a relatively modest effect on
PSA levels [52]. Thus, a rising PSA level should not, on its
own, be an indication to stop therapy with radium-223 [53].
C. Parker et al.
Similarly, although radium-223 has been shown to
reduce pain in some patients [18, 54], a lack of pain
response should not necessarily be regarded as an indication
to stop treatment [52].
Monitoring radium-223 safety
Because treatment with radium-223 may cause myelosup-
pression, blood cell count monitoring should be done at
baseline and before each injection. Before the ﬁrst dose of
radium-223, the patient’s absolute neutrophil count (ANC)
should be ≥1.5× 109/L and platelet count ≥100× 109/L.
Before subsequent radium-223 doses, ANC should be ≥1×
109/L and platelet count ≥50× 109/L. If these values do not
recover within 6–8 weeks after the last radium-223 dose,
then radium-223 should be discontinued [43,45].
In our clinical experience, non-hematologic AEs with
radium-223, such as transient diarrhea, have been uncom-
mon and rarely require intervention. Treatment dis-
continuations related to toxicities have been rare in our
practice. Other reasons for discontinuation of radium-223
therapy before the completion of 6 treatment cycles include
Table 3 Key elements for patient education
Topic Key points to emphasize
Multidisciplinary team approach • Explain the role of each member in ensuring optimal patient care and outcomes
Rationale for choosing Ra-223 • Describe mechanism of action
• Explain survival beneﬁt
• Review low incidence of adverse events and types of events to expect
Treatment guidelines • Review place of radium-223 in treatment guidelines
• ESMO and NCCN recommend radium-223 with highest level of evidence for both ﬁrst- and second-line
therapy
• Also recommended by AUA and EAU
• Highest rating by ESMO-MCBS
Treatment course • Emphasize importance of adhering to treatment for the full course to derive maximum beneﬁt
• Explain that a rising PSA or lack of pain response is not necessarily an indication of lack of efﬁcacy
• Radium-223, similar to immunotherapy, does not target the androgen receptor axis and has a relatively
modest effect on PSA levels
Concomitant medications • Safe when combined with ADT and traditional hormonal therapy
• Safe when administered with EBRT
• According to preliminary data, not safe when combined with abiraterone acetate and prednisone
• Chemotherapy contraindicated until further data are available
Radiation safety • Reassure patients about minimal risk to patient and caregivers
• Low levels may be present in blood, urine, and mainly stool during ﬁrst week after treatment and in bone
during weeks after treatment
• Patients and caregivers should use gloves and follow universal precautions when handling bodily ﬂuids
and waste
•Good hygiene practices should be followed for at least 1 week after the last injection
•Clothing soiled with patient fecal matter should be washed promptly and separately from other clothing
• Patients who are sexually active should use condoms and their female partners should use a highly
effective method of birth control during treatment and for 6 months following completion of treatment if
reproductive potential exists
• Cremation or burial of a body that had been administered radium-223 does not present a signiﬁcant risk to
crematorium personnel or individuals preparing a body for subsequent burial
• Pregnant women should not handle radium-223 unless wearing gloves and using proper protection (e.g.,
barrier gowns)
• Provide and review instructions for radiation safety
Monitoring efﬁcacy and safety • Explain that conventional measures of response (e.g., reduction in PSA) may be of limited value because of
the different mechanism of action of radium-223; thus, ALP and imaging studies may also be used to monitor
treatment response and disease progression
• Safety monitoring based on regular blood counts and adverse events
Abbreviations: ADT androgen deprivation therapy, ALP alkaline phosphatase, AUA American Urological Association, EAU European Association
of Urology, EBRT external beam radiation therapy, ESMO European Society for Medical Oncology, MCBS magnitude of clinical beneﬁt scale,
NCCN National Comprehensive Cancer Network, PSA prostate-speciﬁc antigen.
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evidence of visceral metastases or rapid disease progression
that precludes achieving a treatment response [55]. Long-
term (up to 3 years) patient follow-up data from the phase 3
trial showed that radium-223 was well tolerated with a low
incidence of myelosuppression and no clinical evidence of
long-term safety concerns, such as secondary malignancies
or bone marrow failure. Although the possibility of such
long-term safety concerns occurring beyond 3 years is
unknown, the current safety results are encouraging.
Additional considerations and precautions in speciﬁc
clinical situations
Given the very short range of the alpha-particles and very
low emission of gamma photons, treatment with radium-223
does not pose a radiation risk to healthcare professionals.
Based on available evidence, no contact restrictions are
required for reasons of radiation protection. However, it is
important to avoid internal contamination with radium-223.
During the ﬁrst week after administration, low levels of
radium-223 may be present in blood, urine, and stool.
Moreover, as radium-223 targets the areas of active bone
turnover, measurable amounts will be found in bone in the
weeks after treatment. When taking the normal precautions
that are common practice for healthcare professionals (e.g.,
preventing transmission of blood-borne infections, such as
viral hepatitis), the risks for internal contamination are
negligible, even during surgical procedures involving bone.
Discussions with the patient and their caregiver at
the start of radium-223 therapy
The healthcare provider has a responsibility to explain to the
patient and their caregiver all of the approved options that are
available to treat mCRPC, the rationale for selecting radium-
223, and what the patient might expect during treatment
(Table 3). The patient should also be made aware that they may
eventually receive all other available therapies as needed to
control their disease and increase survival over the course of
treatment (including docetaxel [56], abiraterone [21], enzalu-
tamide [17], cabazitaxel [19], and sipuleucel-T [57]) whether in
combination or sequentially [58–60], depending on drug
availability and reimbursement limitations. As part of this
discussion, it should be noted that although there are no con-
traindications for concomitant administration of radium-223
with other approved CRPC therapies (such as abiraterone or
enzalutamide), the concomitant administration of chemother-
apy or other systemic radioisotopes with radium-223 is con-
traindicated owing to concerns of myelosuppression [43,45].
As a bone-seeking calcium mimetic, radium-223 accu-
mulates in hydroxyapatite areas surrounding tumor lesions
where it binds to newly formed bone stroma in osteoblastic
metastases [61, 62]. For patients, it can be helpful to explain
the similarity between radium and calcium, emphasizing
that radium-223 activity is concentrated in the bone, with
limited penetration into soft tissues [61, 62]. A discussion of
the most frequently experienced AEs associated with
radium-223 will prepare the patient for what to expect
during treatment (Table 3) [18].
Patients may be wary of an alpha radiation therapy, so it
is also important to explain that the radiation risk is minimal
for persons they would come into contact with during
treatment, such as their family members [63]. The necessary
precautions to ensure radiation safety are much less strin-
gent for radium-223 compared with other well-known
radionuclide treatments. Whereas, for example, iodine-131
treatment for thyroid cancer demands hospital admission in
shielded rooms and stringent restrictions on direct contact
with family and caregivers, the precautions after
radium-223 are less demanding. Radium-223 can be
administered on an outpatient basis, and there are no
restrictions regarding contact with other people immediately
after treatment [45] because the alpha-particles emitted by
radium-223 only travel a fraction of a millimeter within the
body [64]. Radium-223 is rapidly cleared from the blood
and primarily distributed into bone or excreted into the
intestine, with ~63% of the administered radioactivity being
excreted from the body within 7 days post injection [45].
Because radium-223 is eliminated through feces, patients
and their caregivers should use gloves and follow universal
precautions for patient care when handling bodily ﬂuids and
waste to avoid contamination. In general, good hygiene
practices should be followed while receiving radium-223
and for at least 1 week after the last injection to minimize
the risk of radiation exposure from bodily ﬂuids to house-
hold members and caregivers.
It is also helpful to inform patients that radium-223 does
not target the androgen receptor and has a relatively modest
effect on PSA levels [52]. Consequently, the patient should be
made aware that the absence of a PSA response with radium-
223 treatment does not necessarily imply a lack of efﬁcacy.
Part of the physician-patient discussion should focus on
the importance of adhering to treatment. The recommended
dose regimen of radium-223 is 55 kilobecquerel (kBq) per
kilogram of body weight given by slow intravenous injec-
tion over 1 min at 4-week intervals for a total of six injec-
tions [43,45]. An analysis of the open-label, single-arm,
phase 3b, international expanded access program for
patients with bone-predominant mCRPC found that median
OS was greater in patients who received 5–6 injections vs
those who received 1–4 injections [65]. Similarly, an OS
advantage for patients who received 5–6 injections vs those
who received 1–4 injections was seen in post hoc subgroup
analyses of the US expanded access program and
ALSYMPCA [66]. This suggests that 5 or 6 cycles of
treatment might be more effective than fewer cycles,
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although this was not a randomized comparison. Additional
clinical data and/or experience may be necessary to deter-
mine whether there is an optimal number of cycles. To this
end, a randomized clinical trial is ongoing to assess
symptomatic skeletal event-free survival and OS for various
doses and regimens of radium-223 (NCT02023697).
Coordination of care and treatment considerations
Optimal management of patients with mCRPC involves
working with a multidisciplinary team that could include a
medical oncologist, urologist, radiation oncologist, and nuclear
medicine physician and nurse [67]. From a practical standpoint,
staff will need to be trained and educated on safe handling and
administration of radium-223 [52]. In many countries nuclear
medicine specialists will administer radium-223 [55], although
the role of nuclear medicine physicians may vary among
countries. For example, healthcare providers in a community
setting or institution may not have direct access to a nuclear
medicine specialist or radiation oncologist [55]. The role of
oncologists and urologists may also differ depending on the
geographical region or institution, so it is important that the
treating physician works with their colleagues based on what is
best for the patient in their country or facility [67]. Countries
vary in their applicable laws, licenses, and rules on handling
and administering radioactive substances. For example, US
physicians must have Nuclear Regulatory Commission
licensure to administer radium-223; therefore, it is invari-
ably administered by nuclear medicine radiologists or
radiation oncologists. In Sweden, radium-223 is prescribed
by the oncologist and administered by nuclear medicine
radiologists. Because of such differences, compliance with
national practices for handling radiopharmaceuticals is
essential, and the nuclear medicine physician on the team is
typically the most qualiﬁed to make arrangements.
Conclusions
Treatment options for patients with mCRPC have expanded
in recent years to include radium-223, a targeted alpha
therapy. Based on our collective clinical experience, we
recommend that radium-223 be considered relatively early
in the course of treatment in patients with mCRPC with bone
metastases before they develop visceral disease. Speciﬁcally,
in patients who progress after receiving hormonal therapy,
initiation of radium-223 or chemotherapy may be preferable
to switching to another hormonal therapy because of the
limited efﬁcacy resulting from cross-resistance. This is parti-
cularly important because the clinical window of opportunity
for radium-223 exists before the development of visceral
metastases, which would render the patient ineligible for
radium-223 treatment. Initial ﬁndings from the ERA 223
phase 3 clinical trial advise against the combination of
radium-223 with abiraterone and prednisone. Coordination of
care among multidisciplinary team members, patients, and the
patients’ caregivers is essential for optimizing the safe and
effective treatment of all CRPC therapies.
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